PARP1 and neoplasm: Figure 2 delineates how DDR abnormalities at genomic, proteomic, and pathway levels converge to suppress anti-tumor immunity. The reduced p-STING in PARP1-high tumors directly links DDR over-activation to STING pathway exhaustion, supporting its inclusion in the DDR-IF score (29).